SCHEMBL940795

SCHEMBL940795

C1=C2NCCNC2NCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717919 0.84
SCHEMBL16496273 0.81
SCHEMBL28244684 0.70
SCHEMBL16237326 0.67 CHRNB2 (0.34)
SCHEMBL16237824 0.67 CHRNB2 (0.34)
SCHEMBL3463114 0.62
SCHEMBL234698 0.62
SCHEMBL27467506 0.62 NISCH (0.34)
SCHEMBL24783209 0.61 CHRNB2 (0.31)
SCHEMBL22755811 0.60 SLC18A3 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492199-B2 Pyridopyrimidines as histamine H4-receptor inhibitors FAES FARMA, S.A. (ES) 2025-12-09 US disclosed
CN-112739699-B Pyridopyrimidine compounds as histamine H4 receptor inhibitors 费斯制药股份有限公司 2023-11-28 CN disclosed
EP-3827005-B1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA SA (ES) 2022-08-17 EP disclosed
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2021-09-30 US disclosed
EP-3827005-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2021-06-02 EP disclosed
CN-112739699-A Pyridopyrimidine compounds as histamine H4 receptor inhibitors 费斯制药股份有限公司 2021-04-30 CN disclosed
WO-2020020939-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2020-01-30 WO disclosed
EP-2914267-B1 THERAPY FOR CONSTIPATION LAMB BLAIR G (CA) 2018-12-12 EP disclosed
US-9616066-B2 Therapy for constipation 2294719 ONTARIO LIMITED (CA) 2017-04-11 US disclosed
US-20170065599-A9 THERAPY FOR CONSTIPATION 2294719 ONTARIO LIMITED (CA) 2017-03-09 US disclosed
US-7538110-B2 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction ADOLOR CORPORATION (US) 2009-05-26 US disclosed
CN-101355951-A Novel opioid antagonists ADOLOR CORP (US) 2009-01-28 CN disclosed
EP-1940412-A2 NOVEL OPIOID ANTAGONISTS Adolor Corporation (US) 2008-07-09 EP disclosed
EP-1940412-A2 NOVEL OPIOID ANTAGONISTS Adolor Corporation (US) 2008-07-09 EP disclosed
WO-2007050802-A3 NOVEL OPIOID ANTAGONISTS ADOLOR CORP (US) 2007-11-22 WO disclosed
US-20070105863-A1 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction MERCK SHARP & DOHME LLC 2007-05-10 US disclosed
US-20070105863-A1 e.g. 1-(8-(3-hydroxyphenyl)-7,8-dimethyl-hexahydro-1H-pyrido[1,2- alpha ]pyrazin-2(6H)-yl)-2-phenylethanone; analgesics; gastrointestinal dysfunction, post-surgical recovery; side effect reduction MERCK SHARP & DOHME LLC 2007-05-10 US disclosed
WO-2007050802-A2 NOVEL OPIOID ANTAGONISTS ADOLOR CORPORATION (US) 2007-05-03 WO disclosed
WO-2007050802-A2 NOVEL OPIOID ANTAGONISTS ADOLOR CORPORATION (US) 2007-05-03 WO disclosed
JP-2001064178-A 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-A] PYRAZINE DERIVATIVE AS A LIGAND TO SEROTONIN RECEPTOR PFIZER PROD INC 2001-03-13 JP disclosed